RVMD - Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancrea
RVMD - Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer Link To Story from REVMED.com
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.